City Therapeutics Inc. (CTY)
$21.46-4.20%Close
Snapshot
- 1 week
- -4.2%-2.7% vs SPY
- Market cap
- $208.6M
- P/E
- negindustry 14.4
- P/B
- 0.0
- EV/EBITDA
- 1.6
Signal: Call, Regime, Alignment, Score, ATR trend, HiLo flip, Coil, Exhaustion, Topping · Technicals (EMA stack, slope, squeeze, stochastic, MACD-Z, DI+) · Price & returns: 3 months, Year to date, 1 year
Price & returns: 3 years, 5 years
Signal: Composite · Performance (Q-Score, Sharpe, Sortino, Calmar, CAGR, drawdown, alpha)
Signal evidence
Best Combo (today's action, held-out profit factor and family votes) · White Arrow (the call, its profit factor and closed trades) · Regime (today's regime and the regime model's profit factor) · Exhaustion (whether buyers or sellers are stretched today and the latest release)
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company
About
City Therapeutics Inc. (CTY). City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA. The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets. Its R&D pipeline includes programs addressing thromboembolic diseases (targeting Factor XI), Stargardt…
Profile
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUS
CEOAndrew C. Orth
IPOOct 16
Employees75
Shares outstanding9.7M
Float-
Free float-
Websitecitytx.com
Key executives
- Andrew C. OrthPresident, CEO & DirectorUSD 677K
- Tracy ZimmermannChief Scientific OfficerUSD 667K
- Baisong MeiChief Medical OfficerUSD 528K
- John Michael MaraganoreCo-Founder & Executive ChairUSD 200K
- Ari NowacekCo-Founder & SVP of Corporate Development
- Kotaro NakanishiCo-Founder & Scientific Advisor
Fundamentals
SCORES & PROFILE
FUND, Value, Growth and GARP scores and the archetype
ROIC11.0%
REV YoY-
ROE18.3%
EPS YoY-
ROA8.7%
GROSS70
OP35
NET22
VALUATION
P/E TTM0.00
P/E FWD-
SECTOR PE20.69
INDUSTRY PE14.42
P/B0.00
P/FCF-
EV/EBITDA1.61
EV/EBIT-
FCF YIELD-
TRUE FCF YLD-
PEG-
Risk
INT COV-
D/E58.82
ALTMAN Z-
CURR RATIO0.73
ND/EBITDA1.55
